| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3Ks), showcasing unique interactions with the enzyme's active site. Its structure allows for specific binding, disrupting lipid signaling pathways crucial for cellular processes. The compound's reactivity is influenced by its ability to form covalent bonds with key residues, altering enzymatic activity and downstream signaling. This selective inhibition leads to distinct kinetic profiles, emphasizing its role in modulating cellular responses. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
This inhibitor targets the BCR-ABL kinase, which is overactive in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Another BCR-ABL inhibitor used for CML and GISTs, with a broader spectrum of kinase inhibition compared to imatinib. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
This inhibitor targets the epidermal growth factor receptor (EGFR) kinase. | ||||||
Lapatinib ditosylate | 388082-78-8 | sc-202205B sc-202205 sc-202205A | 5 mg 10 mg 25 mg | $49.00 $77.00 $117.00 | 15 | |
A dual EGFR and HER2 inhibitor, used in breast cancer therapy when HER2 is overexpressed. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
A multi-kinase inhibitor targeting RAF, VEGFR, and PDGFR kinases, approved for advanced renal cell carcinoma and hepatocellular carcinoma. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Another multi-kinase inhibitor targeting VEGFR, PDGFR, KIT, and others, used in renal cell carcinoma and gastrointestinal stromal tumors. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
An inhibitor of Janus kinases (JAKs), used for myelofibrosis and polycythemia vera. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
This inhibitor targets Bruton's tyrosine kinase (BTK), used for CLL, mantle cell lymphoma, and other B-cell malignancies. | ||||||